Drive DeVilbiss Healthcare, a world leading manufacturer of oxygen solutions and Sanrai International, an expert in underserved markets, held the global unveiling of the new PulmO2 10 L Oxygen Concentrator.

The two organizations partnered together to develop a new generation of oxygen concentrator fit for purpose worldwide. The PulmO2 is energy efficient, resilient, and adapted to a clinical environment. The product development and unveiling was supported by the UK government’s Foreign, Commonwealth, and Development Office (FCDO) with Professor Charlotte Watts CMG FMedSci, FCDO Chief Scientific Adviser and Director for Research and Evidence commenting:

“UK International Development is delighted to see the unveiling of the PulmO2 Oxygen Concentrator and the ground-breaking innovations for low-resource environments that have been designed into this product.  As part of our wider support for oxygen innovation, we hope that the PulmO2 will be a significant step forward in providing oxygen to patients that need life-saving oxygen across the world, particularly in low-resource settings.”

The unveiling was followed by a deeper dive into the technology advancements along with important discussions about how to effectively make oxygen available in hard to reach environments.

Speaking at the unveiling, Oliver Niemann, Group Managing Director of Drive DeVilbiss International said: “The PulmO2 is the first time an oxygen concentrator was explicitly designed for harsher clinical environments with an entirely different use case compared to the traditional European and American homecare markets. Our engineers in Somerset, Pennsylvania did a great job in interpreting specifications from UNICEF’s target product profile to rapidly develop a device that can reliably produce oxygen for patients anywhere in the world.”

With energy efficiency of up to 64% compared to traditional 10L oxygen concentrators, by using the PulmO2, hospitals and clinics can save a significant amount in energy costs. The PulmO2 is also engineered to be robust and resilient in harsh environments, even when only being used for short periods of time to treat acute respiratory disease exacerbations. Overall, these innovations reduce the total cost of ownership compared to existing concentrators, enabling stretched hospital and government budgets cost effectively prioritize oxygen availability.

Drive DeVilbiss and Sanrai continued showing the PulmO2 along with their entire range of respiratory and other innovative medical devices throughout Arab Health. Together, they are leading the way in developing fit for purpose products for unique environments bringing oxygen to every patient in need worldwide.